BARX2 and sarcoma: Except for those cancers [ACC, adrenocortical carcinoma; DLBC, diffuse large B-cell lymphoma; LAML, acute myeloid leukaemia; LGG, brain lower grade glioma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; SARC, sarcoma; TGCT, testicular germ cell tumour; THYM, thymoma; UCS Uterine Carcinosarcoma; UVM, uveal melanoma] for which normal tissue data were unavailable or too limited, significant differences in BARX2 expression between tumour and normal tissue were found in 22 types of cancer.